Clinical Correlations of WTX Inactivation in Wilms Tumor

陈旧的应用程序的广泛、长期目标和具体目标，参考与健康相关的 项目(即与该机构使命的相关性)。简明扼要地描述实现这些目标的研究设计和方法。描述 你将用来追求这些目标的基本原理和技术。 此外，用两三句简单明了的话描述这项研究与公共卫生的相关性。如果应用程序得到资助，则此 原样的描述将成为公开信息。因此，不包括专有/机密信息。不要超过空格 ProVideo 肾母细胞瘤是最常见的儿童肾癌，与肾脏发育密切相关。 WT1和β-连环蛋白两个基因的突变和胰岛素样生长因子2的表观遗传变化 (IGF2)基因座已被描述，但大多数病例的遗传学基础仍不清楚。vt.给出 目前治疗肾母细胞瘤的方案取得了很高的成功率(85%)，因此迫切需要 寻找可以指导临床治疗的预后标记物，但这些标记物很难定义。我们有 最近发现了位于X染色体上的一种新的肿瘤抑制基因WTX，它在 肾母细胞瘤占30%。我们现在建议在我们的初步发现的基础上建立临床相关性 检测WTX基因突变对预后的潜在应用价值。我们会的 还通过识别受WTX失活影响的分子途径来定义其他标记 总之，这些研究将通过在Wilms中定义新的生物标记物来实现直接的翻译目标 并将进一步加深我们对这种疾病的了解，使未来能够发展基于生物学的 治疗。具体目的：1)明确肾母细胞瘤WTX失活的临床相关性。我们会 分析200个Wilms肿瘤的WTX突变，并将我们的发现与疾病转归和其他 临床参数，如出现症状时的年龄、诊断阶段、双侧性和相关 发育畸形。我们还将开发WTX多克隆抗体和Wilms肿瘤抗体 微阵列检测WTX蛋白水平。2)对WTX功能进行建模以确定潜在的临床途径 意义。我们将使用标记WTX的免疫沉淀和质谱学来确定 WTX与其他细胞成分之间的相互作用。这些相互作用的功能后果 将在体外使用肾脏来源的细胞系进行验证，并在体内使用WTX条件基因敲除小鼠进行验证。 3)新的Wilms肿瘤标志物的临床验证。参与WTX相关途径的基因将被测试 通过将表达水平与临床参数相关联，将其作为生物标志物潜在的临床应用。我们 还将在原发肾母细胞瘤中测试选定的突变基因。我们预计，通过定义 预后标记物和进一步加深我们对肾母细胞瘤WTX相关通路的了解，该项目将 在治疗儿童肾癌方面有公共卫生应用。

Stale the application's broad, long-term objectives and specific aims, making reference to ttie health relatedness of the project (i.e., relevance to the mission of the agency). Describe concisely the research design and methods for achieving these goals. Describe the rationale and techniques you will use to pursue these goals. In addition, in two or three sentences, describe in plain, lay language the relevance of this research to public health. If the application is funded, this description, as is, will become public infonnation. Therefore, do not include proprietary/confidential infonnation. DO NOT EXCEED THE SPACE PROVIDEO Wilms tumor is the most common pediatric kidney cancer and is closely connected to kidney development. Mutafions in two genes, WT1 and beta-catenin, and epigenefic changes in the insulin-like growth factor 2 (IGF2) locus have been described but the genetic basis of the majority of cases remains unknown. Given that current treatment protocols for Wilms tumor achieve high success rates (85%), there is a pressing need for prognosfic markers that can guide clinical management but these have been difficult to define. We have recently identified a novel tumor suppressor located on the X chromosome, WTX, which is inactivated in 30% of Wilms tumor cases. We now propose to build on our initial findings to establish clinical correlates of WTX inacfivafion and to test the potenfial applicafion of WTX mutafions as markers of prognosis. We wil also define additional markers by identifying molecular pathways that are affected by WTX inactivation Together, these studies will achieve immediate translational goals by defining novel biomarkers in Wilms tumor and will further our understanding of this disease to allow the future development of biologically based therapies. Specific aims: 1) To define clinical correlafions of WTX inactivation in Wilms tumor. We will analyze 200 Wilms tumors for WTX mutations and correlate our findings with disease outcomes and other clinical parameters such as age at presentation, stage at diagnosis, bilaterality and associated developmental malformafions. We will also develop a WTX polyclonal antibody and a Wilms tumor fissue microarray to test WTX protein levels. 2) Modeling WTX funcfion to identify pathways of potential clinical significance. We will use immunoprecipitation of tagged WTX followed by mass spectrometry to define interactions between WTX and other cellular components. The funcfional consequences of these interactions will be validated in vitro using kidney derived cell lines and in vivo using a WTX conditional knockout mouse. 3) Clinical validation of novel Wilms tumor markers. Genes involved in WTX related pathways will be tested for potenfial clinical applicafions as biomarkers by correlafing expression levels with clinical parameters. We will also test selected genes for mutafions in primary Wilms tumors. We anticipated that, by defining prognostic markers and furthering our knowledge of WTX related pathways in Wilms tumor, this project will have public health applications in the treatment of pediatric kidney cancer.